{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:12:44Z","timestamp":1747149164034,"version":"3.40.5"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2024,3]]},"abstract":"Introduction<\/jats:title>Small cell bladder cancer is a relatively rare tumor, representing <1% of all bladder tumors. Amrubicin monotherapy is used as second\u2010line treatment for small cell lung cancer in Japan.<\/jats:p><\/jats:sec>Case presentation<\/jats:title>A 79\u2010year\u2010old woman presented with gross hematuria and was diagnosed with small cell bladder cancer (T2 or higher). Neoadjuvant chemotherapy with etoposide and cisplatin resulted in a partial response. Robot\u2010assisted radical cystectomy was performed, and radical resection was achieved. As we identified metastasis in the pleura 1\u2009year later, we administered carboplatin and etoposide, which resulted in a partial response. Although pembrolizumab was initiated as maintenance therapy, it was not effective. Amrubicin was given as third\u2010line therapy, and stable disease was achieved without serious adverse effect for 6\u2009months.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Although there is no established treatment for metastatic small cell bladder cancer, the current case report suggests the effectiveness of amrubicin in this setting.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iju5.12684","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T13:14:20Z","timestamp":1702991660000},"page":"127-130","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A\u00a0case\u00a0report"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4600-7350","authenticated-orcid":false,"given":"Kazutaka","family":"Mitani","sequence":"first","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-8262","authenticated-orcid":false,"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0968-4369","authenticated-orcid":false,"given":"Gen","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Yosioka","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-3156","authenticated-orcid":false,"given":"Shuhei","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7888-0314","authenticated-orcid":false,"given":"Hirochika","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Nagami","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-2192","authenticated-orcid":false,"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.09.001"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38901-2"},{"key":"e_1_2_11_4_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology bladder cancer. Version 3.2023."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1154685"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-160"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14729"},{"key":"e_1_2_11_8_1","first-page":"313","article-title":"A case of small cell carcinoma of the bladder","volume":"66","author":"Ota H","year":"2020","journal-title":"Hinyokika Kiyo"},{"key":"e_1_2_11_9_1","first-page":"34","article-title":"Metastatic small cell carcinoma of the urinary bladder treated with systemic chemotherapy including an AMRUBICIN; a CASE report","volume":"107","author":"Naito A","year":"2016","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.577"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163953"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01269-9"},{"key":"e_1_2_11_14_1","article-title":"Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi\u2010institutional, single\u2010arm phase 2 study","volume":"2","author":"Akamatsu H","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938"}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T09:26:25Z","timestamp":1709457985000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.12684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/iju5.12684"],"URL":"https:\/\/doi.org\/10.1002\/iju5.12684","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"type":"print","value":"2577-171X"},{"type":"electronic","value":"2577-171X"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"2023-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}